Corcept Therapeutics Incorporated (CORT) Financial Statements & Analysis

Corcept Therapeutics Incorporated (CORT) Income Statement

Corcept Therapeutics Incorporated reported revenue of $761.41M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 12.8% from $675.04M a year earlier. Net income was $98.17M, down 29.7% year over year, a net margin of 12.9%. Gross margin was 98.3% and operating margin 5.9%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $256.15M, up 31.7% from the same quarter a year earlier.

Corcept Therapeutics Incorporated Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Corcept Therapeutics Incorporated income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	761.41	675.04	482.38	401.86	365.98	353.87	306.49	251.25	159.20
Cost of Revenue	12.98	10.88	6.48	5.39	5.28	5.58	5.50	5.22	3.55
Gross Profit	748.43	664.16	475.89	396.47	360.70	348.29	300.98	246.03	155.65
Operating Expenses
Research & Development	254.91	246.89	184.35	130.99	113.86	114.76	89.02	75.25	40.38
Selling, General & Administrative	448.73	280.32	184.26	152.85	122.36	105.33	100.36	81.29	62.42
Operating Expenses	703.63	527.21	368.61	283.84	236.22	220.09	189.38	156.54	102.79
Operating Income	44.80	136.95	107.28	112.63	124.48	128.20	111.61	89.50	52.86
Other Income/Expense
Interest Income	21.67	24.54	17.28	3.56	0.53	3.40	5.07	2.66	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05
Other Income/Expense	21.67	24.54	17.28	3.56	0.53	3.40	5.07	2.66	-0.05
Income
Income Before Tax	66.46	161.49	124.56	116.19	125.01	131.60	116.68	92.15	52.81
Income Tax Expense	-33.19	20.28	18.42	14.77	12.49	25.59	22.50	16.74	-76.32
Net Income	98.17	139.73	105.50	101.42	112.51	106.01	94.18	75.41	129.12
Net Income - Continuous Operations	99.65	139.73	106.14	101.42	112.51	106.01	94.18	75.41	129.12
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	45.95	162.83	108.32	116.08	127.95	130.44	113.78	89.73	52.96
EBIT	44.80	136.95	107.28	112.63	124.48	128.20	-	-	-
Depreciation & Amortization	1.89	1.34	1.04	3.45	3.07	2.24	2.17	0.24	0.11
Earnings Per Share
Basic EPS	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Diluted EPS	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Basic Shares Outstanding	103.86	103.23	103.56	106.79	115.65	115.41	114.35	125.68	113.53
Diluted Shares Outstanding	119.99	113.48	111.74	115.97	125.96	124.19	122.57	126.69	124.52

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Corcept Therapeutics Incorporated Financial Statements

What was Corcept Therapeutics Incorporated's revenue in fiscal 2025?

Corcept Therapeutics Incorporated reported revenue of $761.41M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 12.8% from $675.04M a year earlier.

Is Corcept Therapeutics Incorporated profitable?

Yes. Corcept Therapeutics Incorporated earned net income of $98.17M in fiscal 2025, a net margin of 12.9%. In fiscal 2024 it earned $139.73M.

What is Corcept Therapeutics Incorporated's operating margin?

Corcept Therapeutics Incorporated's operating income was $44.80M on revenue of $761.41M in fiscal 2025, an operating margin of 5.9%, compared with 20.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition